On 1 July, European Regulation 2019/933 enters into force, marking the end of a long journey for the generics and biosimilars industries in its pursuit of a waiver to allow manufacturing for export outside the European Union – as well as stockpiling for day-one launch within the EU – during the term of supplementary protection certificates.
Amending the European SPC Regulation 469/2009, the waiver Regulation is the culmination of more than a decade of lobbying efforts...





